HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya
作者： H. N. Kim , J. Scott , A. Cent , L. Cook , R. A. Morrow
DOI: 10.1111/J.1365-2893.2011.01466.X
关键词:
摘要: Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance HIV-HBV co-infected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV-infected adults before and for 18 months after starting highly-active with stavudine, nevirapine. Twenty-seven (6.9%) were HBsAg(+) anti-HBs negative: 24 HBeAg-negative, had HBV DNA ≤10,000 IU/ml. Sustained suppression <100 IU/ml occurred 89% 19 evaluable patients. Resistance only 2 subjects, both high baseline levels. Lamivudine can emerge the setting incomplete but was infrequently observed among low
sci-hub.se 参考文章(29)
A Mithat Bozdayi, Ersin Karatayli, Handan Kayhan, A Resat Türkyilmaz, Selim Karayalçin, Fikret Sahin, Hayri Karaaslan, Cihan Yurdaydin, A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antiviral Therapy. ,vol. 12, pp. 761- 768 ,(2007)
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study JAMA Internal Medicine. ,vol. 166, pp. 1632- 1641 ,(2006) , 10.1001/ARCHINTE.166.15.1632
Angel Mei-Ling Chim, Joseph Jao-Yiu Sung, Henry Lik-Yuen Chan, Junqi Niu, Hao Wang, Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antiviral Therapy. ,vol. 12, pp. 345- 353 ,(2007)
Gail V. Matthews, Anchalee Avihingsanon, Sharon R. Lewin, Janaki Amin, Rungsun Rerknimitr, Panusit Petcharapirat, Pip Marks, Joe Sasadeusz, David A. Cooper, Scott Bowden, Stephen Locarnini, Kiat Ruxrungtham, Gregory J. Dore, A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand Hepatology. ,vol. 48, pp. 1062- 1069 ,(2008) , 10.1002/HEP.22462
Man-Fung Yuen, Erwin Sablon, Chee-Kin Hui, He-Jun Yuan, Hilde Decraemer, Ching-Lung Lai, Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. ,vol. 34, pp. 785- 791 ,(2001) , 10.1053/JHEP.2001.27563
Reena Shah Harania, Jane Karuru, Mark Nelson, Justin Stebbing, HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS. ,vol. 22, pp. 1221- 1222 ,(2008) , 10.1097/QAD.0B013E32830162A8
Gail V Matthews, Angeline Bartholomeusz, Stephen Locarnini, Anna Ayres, Joe Sasaduesz, Eric Seaberg, David A Cooper, Sharon Lewin, Gregory J Dore, Chloe L Thio, Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. ,vol. 20, pp. 863- 870 ,(2006) , 10.1097/01.AIDS.0000218550.85081.59
Daniel Lavanchy, Chronic viral hepatitis as a public health issue in the world Best Practice & Research Clinical Gastroenterology. ,vol. 22, pp. 991- 1008 ,(2008) , 10.1016/J.BPG.2008.11.002
Ching‐Lung Lai, Jules Dienstag, Eugene Schiff, Nancy W. Y. Leung, Mark Atkins, Christine Hunt, Nathaniel Brown, Mary Woessner, Richard Boehme, Lynn Condreay, Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B Clinical Infectious Diseases. ,vol. 36, pp. 687- 696 ,(2003) , 10.1086/368083
François Rouet, Marie‐Laure Chaix, André Inwoley, Philippe Msellati, Ida Viho, Patrice Combe, Valériane Leroy, François Dabis, Christine Rouzioux, ANRS 1236 DITRAME‐B&C Study Group, HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. Journal of Medical Virology. ,vol. 74, pp. 34- 40 ,(2004) , 10.1002/JMV.20143